https://www.helyx.healthcare 2026-04-04T21:17:41.046Z weekly 1 https://www.helyx.healthcare/chi-siamo 2026-04-04T21:17:41.046Z weekly 0.8 https://www.helyx.healthcare/contattaci 2026-04-04T21:17:41.046Z weekly 0.8 https://www.helyx.healthcare/informazione 2026-04-04T21:17:41.046Z weekly 0.8 https://www.helyx.healthcare/formazione 2026-04-04T21:17:41.046Z weekly 0.8 https://www.helyx.healthcare/eventi 2026-04-04T21:17:41.046Z weekly 0.8 https://www.helyx.healthcare/comunicazione-strategica 2026-04-04T21:17:41.046Z weekly 0.8 https://www.helyx.healthcare/analisi-di-scenario 2026-04-04T21:17:41.046Z weekly 0.8 https://www.helyx.healthcare/medical-writing 2026-04-04T21:17:41.046Z weekly 0.8 https://www.helyx.healthcare/medical-communication 2026-04-04T21:17:41.046Z weekly 0.8 https://www.helyx.healthcare/digital-and-clinical-education 2026-04-04T21:17:41.046Z weekly 0.8 https://www.helyx.healthcare/awareness 2026-04-04T21:17:41.046Z weekly 0.8 https://www.helyx.healthcare/advocacy 2026-04-04T21:17:41.046Z weekly 0.8 https://www.helyx.healthcare/privacy 2026-04-04T21:17:41.046Z weekly 0.8 https://www.helyx.healthcare/politica-della-qualita 2026-04-04T21:17:41.046Z weekly 0.8 https://www.helyx.healthcare/aboutmedicine-eng 2026-04-04T21:17:41.046Z daily 0.7 https://www.helyx.healthcare/aboutmedicine-eng/colchicina-nella-modulazione-ad-ampio-spettro-dellinfiammazione-evidenze-cliniche-in-cardiologia-e-in-reumatologia 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/aboutmedicine-eng/relugolix-ct-nella-gestione-di-pazienti-affette-da-endometriosi-esperienze-dalla-pratica-clinica-2 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/aboutmedicine-eng/il-sistema-aid-tandem-mobi-documento-di-consenso-di-un-panel-di-esperti-italiani-per-la-selezione-del-paziente-e-lutilizzo-clinico 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/aboutmedicine-eng/terapia-di-combinazione-nel-paziente-affetto-da-ipertrofia-prostatica-benigna-quanto-e-ancora-attuale 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/aboutmedicine-eng/leuprorelina-acetato-come-trattamento-di-base-per-il-carcinoma-prostatico-metastatico-brca-mutato 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/aboutmedicine-eng/approcci-innovativi-di-empirica-ragionata-nella-gestione-delle-infezioni-ospedaliere-da-gram-negativi-multi-resistenti-agli-antibiotici 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/aboutmedicine-eng/carcinoma-prostatico-localmente-avanzato-in-un-uomo-di-56-anni-gestione-con-terapia-antiandrogenica-prima-della-stadiazione 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/aboutmedicine-eng/trattamento-combinato-con-silodosina-e-dutasteride-in-paziente-con-ipertrofia-prostatica-benigna 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/aboutmedicine-eng/ruxolitinib-nella-gestione-della-mielofibrosi 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/aboutmedicine-eng/gestione-medica-di-una-paziente-con-fibromi-uterini-e-desiderio-riproduttivo 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/aboutmedicine-eng/gestione-terapeutica-neoplasia-prostatica-ormono-sensibile-con-sviluppo-di-secondarismi-ossei-post-trattamento-primario 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/aboutmedicine-eng/ruxolitinib-nella-gestione-della-mielofibrosi-una-raccolta-di-esperienze-cliniche-vol-2 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/aboutmedicine-eng/ruxolitinib-nella-gestione-della-mielofibrosi-una-raccolta-di-esperienze-cliniche-vol-1 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/aboutmedicine-eng/ottimizzare-la-gestione-terapeutica-della-recidiva-biochimica 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/aboutmedicine-eng/efficacia-della-terapia-medica-combinata-nellipertrofia-prostatica-benigna 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/aboutmedicine-eng/un-modello-per-la-stima-del-costo-unitario-delle-iniezioni-intravitreali 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/aboutmedicine-eng/dutasteride-e-silodosina-trattamento-orale-per-lipertrofia-prostatica-benigna 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/aboutmedicine-eng/trattamento-long-term-con-relugolix-ct-dei-fibromi-uterini 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/aboutmedicine-eng/spondiloartrite-assiale-axspa-i-punti-chiave-per-riconoscerla-e-migliorare-il-percorso-di-gestione-multidisciplinare-dei-pazienti-2 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/aboutmedicine-eng/policitemia-vera-e-trombosi-venosa-splancnica-incidenza-diagnosi-e-trattamento 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/aboutmedicine-eng/spondiloartrite-assiale-axspa-i-punti-chiave-per-riconoscerla-e-migliorare-il-percorso-di-gestione-multidisciplinare-dei-pazienti 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/aboutmedicine-eng/le-mutazioni-di-braf-e-met-nel-nsclc-pratica-clinica-e-strategie-a-confronto-2 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/aboutmedicine-eng/fibromatosi-uterina-associata-a-endometriosi-efficacia-e-tollerabilita-di-relugolix-ct-prima-del-trattamento-chirurgico 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/aboutmedicine-eng/trattamento-a-lungo-termine-dei-fibromi-uterini-con-relugolix-40-mg-ct 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/aboutmedicine-eng/malnutrizione-in-oncologia 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/aboutmedicine-eng/gestione-del-paziente-con-carcinoma-della-prostata-ormone-dipendente-esperienze-cliniche 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/aboutmedicine-eng/un-approccio-multidisciplinare-alla-mucopolisaccaridosi-i-dall-identificazione-precoce-alla-terapia-avanzata 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/aboutmedicine-eng/utilizzo-di-ruxolitinib-nella-gestione-del-paziente-con-policitemia-vera-una-raccolta-di-casi-emblematici-vol-3 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/aboutmedicine-eng/gestione-della-paziente-con-carcinoma-mammario-hr-her2-metastatico-in-trattamento-con-ribociclib-una-collection-di-esperienze-cliniche-a-confronto-vol-2 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/aboutmedicine-eng/one-health-una-salute-unica-una-sola-scienza-protect-our-future-too-from-zoonosis 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/aboutmedicine-eng/personalizzazione-della-scelta-dei-sistemi-cgm-esperienze-di-utilizzo-con-il-dispositivo-dexcom-one 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/aboutmedicine-eng/deferiprone-per-il-trattamento-del-sovraccarico-di-ferro-nella-talassemia 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/aboutmedicine-eng/gestione-della-paziente-con-carcinoma-mammario-hr-her2-metastatico-in-trattamento-con-ribociclib-una-collection-di-esperienze-cliniche-a-confronto-vol-1 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/aboutmedicine-eng/indicatori-di-usabilita-dei-sistemi-di-monitoraggio-in-continuo-del-glucosio-il-punto-di-vista-delle-persone-con-diabete 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/aboutmedicine-eng/le-mutazioni-di-braf-e-met-nel-nsclc-pratica-clinica-e-strategie-a-confronto 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/aboutmedicine-eng/utilizzo-di-ruxolitinib-nella-gestione-del-paziente-con-policitemia-vera-una-raccolta-di-casi-emblematici-vol-2 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/aboutmedicine-eng/gestione-dei-fibromi-uterini-il-potenziale-della-terapia-combinata-con-gli-antagonisti-orali-del-gnrh 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/aboutmedicine-eng/melanoma-setting-next-horizon-2023-management-and-targeted-treatment-for-melanoma-braf-patients 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/aboutmedicine-eng/utilizzo-di-ruxolitinib-nella-gestione-del-paziente-con-policitemia-vera-una-raccolta-di-casi-emblematici-vol-1 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/aboutmedicine-eng/rapido-peggioramento-clinico-associato-alla-sospensione-di-everolimus-in-un-giovane-paziente-con-sclerosi-tuberosa 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/aboutmedicine-eng/un-caso-di-sclerosi-tuberosa-dalla-diagnosi-alle-scelte-e-ai-problemi-della-terapia 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/aboutmedicine-eng/efficacia-e-tollerabilita-di-everolimus-in-un-caso-di-epilessia-farmacoresistente-a-esordio-precoce-in-sclerosi-tuberosa 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/aboutmedicine-eng/un-caso-di-epilessia-farmacoresistente-associato-a-tand-tsc-associated-neuropsychiatric-disorders 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/aboutmedicine-eng/sindrome-emolitico-uremica 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/aboutmedicine-eng/utilizzo-della-combinazione-dabrafenib-trametinib-nella-gestione-del-paziente-con-nsclc-in-stadio-avanzato-braf-mutato-esperienze-cliniche-vol-2 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/aboutmedicine-eng/approccio-multidisciplinare-per-la-corretta-gestione-del-paziente-con-lombalgia 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/aboutmedicine-eng/orticaria-cronica-spontanea-i-punti-chiave-per-riconoscerla-e-migliorare-il-percorso-di-gestione-dei-pazienti 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/aboutmedicine-eng/melanoma-sliding-doors-2022-management-and-targeted-treatment-for-melanoma-braf-patients 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/aboutmedicine-eng/presa-in-carico-del-paziente-psoriasico-nellinfanzia-nelleta-adulta-e-nelleta-avanzata 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/aboutmedicine-eng/utilizzo-della-combinazione-dabrafenib-trametinib-nella-gestione-del-paziente-con-nsclc 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/aboutmedicine-eng/climax-psicopatologico-uso-di-cariprazina-nel-trattamento-della-doppia-diagnosi 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/aboutmedicine-eng/gestione-clinica-del-paziente-con-mielofibrosi 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/aboutmedicine-eng/gestione-clinica-del-paziente-con-policitemia-vera 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/aboutmedicine-eng/irbesartan-efficacia-oltre-il-controllo-pressorio 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/aboutmedicine-eng/il-trattamento-dellendometriosi-esperienze-dalla-pratica-clinica-2 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/aboutmedicine-eng/the-roche-diabetes-care-platform-a-new-approach-for-remote-patient-monitoring-and-personalized-diabetes-care 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/aboutmedicine-eng/inibitori-delle-chinasi-ciclina-dipendenti-tumore-della-mammella-terapie 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/aboutmedicine-eng/butterfly-effect-lesordio-di-una-psicosi 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/aboutmedicine-eng/pantoprazolo-le-evidenze-di-una-scelta-consolidata 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/aboutmedicine-eng/utilizzo-della-combinazione-dabrafenib-trametinib-nellalgoritmo-terapeutico-del-nsclc-metastatico-braf-mutato 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/aboutmedicine-eng/utilizzo-della-combinazione-dabrafenib-trametinib-nellalgoritmo-terapeutico-del-nsclc-metastatico-braf-mutato-esperienze-a-confronto 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/aboutmedicine-eng/colangite-biliare-primitiva-condivisione-dei-percorsi-diagnostico-terapeutici-in-seguito-allemergenza-covid-19 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/aboutmedicine-eng/il-trattamento-dellendometriosi-esperienze-dalla-pratica-clinica 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/aboutmedicine-eng/il-setting-adiuvante-del-melanoma-una-continua-conferma 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/aboutmedicine-eng/forward-and-beyond-2-0-management-and-targeted-treatment-for-melanoma-braf-patients 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/aboutmedicine-eng/optimal-management-of-advanced-systemic-mastocytosis-an-emerging-challenge-for-hematologists 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/aboutmedicine-eng/il-ruolo-di-secukinumab-in-dermatologia-oggi 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/aboutmedicine-eng/forward-and-beyond-ridefinire-il-trattamento-del-melanoma-nel-paziente-braf 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/aboutmedicine-eng/effetto-immunomodulante-degli-inibitori-della-tirosina-chinasi-tkis-nel-trattamento-del-carcinoma-renale 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/aboutmedicine-eng/la-combinazione-paracetamolo-caffeina-nelle-cefalee 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/aboutmedicine-eng/la-terapia-sistemica-in-pazienti-adulti-con-dermatite-atopica-moderata-grave 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/aboutmedicine-eng/malattie-infiammatorie-croniche-articolari-la-gestione-multidisciplinare-per-unidentificazione-precoce-dei-fattori-di-rischio-cardiovascolari 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/aboutmedicine-eng/gestione-psicologica-e-clinica-dei-pazienti-con-leucemia-mieloide-cronica-aderenza-alla-terapia-e-treatment-free-remission 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/aboutmedicine-eng/migliorare-lassistenza-dei-pazienti-con-emofilia-dagli-studi-clinici-alla-real-world-experience 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/aboutmedicine-eng/il-patient-journey-ideale-nel-trattamento-adiuvante-del-melanoma-braf-mutato-il-punto-di-vista-di-un-decision-makers-board 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/aboutmedicine-eng/secukinumab-esperienze-cliniche-a-confronto-in-reumatologia 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/aboutmedicine-eng/sclerosi-multipla-trattamento-precoce-a-elevata-efficacia-e-switch-precoce-a-terapie-a-elevata-efficacia 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/aboutmedicine-eng/management-del-paziente-con-leucemia-mieloide-acuta-in-trattamento-con-midostaurina-e-antifungini-azolici 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/aboutmedicine-eng/introduzione-di-ribociclib-come-i-linea-di-trattamento-nel-carcinoma-mammario-avanzato-hr-her2 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/aboutmedicine-eng/value-for-the-future-ripensare-il-presente-per-restituire-il-futuro-roma-30-31-maggio-2019 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/aboutmedicine-eng/terapia-medica-per-il-trattamento-dei-fibromi-nelle-donne-in-eta-fertile 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/aboutmedicine-eng/gastrolesivita-da-fans-nel-paziente-cardiologico 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/aboutmedicine-eng/linfoma-diffuso-a-grandi-cellule-b-dallinnovazione-alla-sostenibilita 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/aboutmedicine-eng/la-diagnosi-clinica-della-dermatite-atopica-delladulto 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/aboutmedicine-eng/rimodulazione-dellappropriatezza-terapeutica-nei-pazienti-con-bpco-quando-come-e-in-quali-pazienti-sospendere-la-terapia-con-steroide-inalatorio 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/aboutmedicine-eng/cheratosi-attinica-e-tumori-cutanei-limportanza-di-una-corretta-prevenzione 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/aboutmedicine-eng/frequenti-versus-non-frequenti-riacutizzatori-gestione-terapeutica-personalizzata-sui-bisogni-del-paziente-con-bpco 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/aboutmedicine-eng/impatto-sulla-salute-pubblica-della-vaccinazione-con-pcv13-negli-adulti 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/aboutmedicine-eng/secukinumab-esperienze-cliniche-a-confronto-in-dermatologia 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/aboutmedicine-eng/profilassi-e-trattamento-dellemicrania-esperienze-cliniche-con-clevia-e-almogran 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/aboutmedicine-eng/la-gestione-del-paziente-con-malattie-infiammatorie-croniche-intestinali-di-grado-moderato-severo-lo-stato-dellarte-in-italia 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/aboutmedicine-eng/mrge-e-problemi-di-motilita-gastrica-i-consigli-del-gastroenterologo-per-una-gestione-ottimale 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/aboutmedicine-eng/un-racconto-in-evoluzione-biosimilari-e-nuove-opportunita-per-clinici-payer-e-pazienti 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/aboutmedicine-eng/come-ottimizzare-la-terapia-inalatoria-e-migliorare-laderenza-terapeutica-nei-pazienti-con-broncopneumopatia-cronica-ostruttiva-bpco 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/aboutmedicine-eng/carcinoma-mammario-metastatico-hr-her2-il-trattamento-con-everolimus-long-responders-esperienze-a-confronto 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/aboutmedicine-eng/il-ruolo-di-secukinumab-nella-strategia-terapeutica-delle-spondiloartriti-focus-sulla-spondilite-anchilosante 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/aboutmedicine-eng/secukinumab-dagli-studi-clinici-alla-pratica-clinica 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/aboutmedicine-eng/il-ruolo-di-secukinumab-nella-strategia-terapeutica-delle-spondiloartriti-focus-sullartrite-psoriasica 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/aboutmedicine-eng/melanoma-2018-per-una-gestione-condivisa-e-mirata-del-paziente-con-mutazione-braf-i-risultati-delle-minifaculties-melanoma-2018 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/aboutmedicine-eng/ruxolitinib-nel-trattamento-della-policitemia-vera-consigli-pratici-per-la-gestione-del-paziente-nella-real-life 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/aboutmedicine 2026-04-04T21:17:41.046Z daily 0.7 https://www.helyx.healthcare/aboutmedicine/chikungunya-dal-rischio-emergente-alla-risposta-preventiva-evidenze-dal-simposio-siti-2025 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/aboutmedicine/contraccezione-ormonale-combinata-con-estetrolo-e-drospirenone-nella-giovane-donna-con-dismenorrea-primaria 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/aboutmedicine/contraccezione-ormonale-combinata-con-estetrolo-e-drospirenone-nella-giovane-donna-alla-prima-esperienza-contraccettiva 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/aboutmedicine/il-grande-classico-prostata-voluminosa-soggetto-in-eta-geriatricaterapia-medica-o-disostruzione 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/aboutmedicine/trattamento-medico-massimale-per-lipertrofia-prostatica-benigna-un-passaggio-indispensabile-prima-di-una-proposta-chirurgica 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/aboutmedicine/trattamento-del-carcinoma-prostatico-localizzato-ad-alto-rischio-focus-sul-paziente-giovane-affetto-da-comorbilita-vascolari 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/aboutmedicine/spot-opt-oculistica 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/aboutmedicine/colchicina-nella-modulazione-ad-ampio-spettro-dellinfiammazione-evidenze-cliniche-in-cardiologia-e-in-reumatologia 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/aboutmedicine/relugolix-ct-nella-gestione-di-pazienti-affette-da-endometriosi-esperienze-dalla-pratica-clinica 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/aboutmedicine/il-sistema-aid-tandem-mobi-documento-di-consenso-di-un-panel-di-esperti-italiani-per-la-selezione-del-paziente-e-lutilizzo-clinico 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/aboutmedicine/terapia-di-combinazione-nel-paziente-affetto-da-ipertrofia-prostatica-benigna-quanto-e-ancora-attuale 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/aboutmedicine/leuprorelina-acetato-come-trattamento-di-base-per-il-carcinoma-prostatico-metastatico-brca-mutato 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/aboutmedicine/approcci-innovativi-di-empirica-ragionata-nella-gestione-delle-infezioni-ospedaliere-da-gram-negativi-multi-resistenti-agli-antibiotici 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/aboutmedicine/carcinoma-prostatico-localmente-avanzato-in-un-uomo-di-56-anni-gestione-con-terapia-antiandrogenica-prima-della-stadiazione 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/aboutmedicine/trattamento-combinato-con-silodosina-e-dutasteride-in-paziente-con-ipertrofia-prostatica-benigna 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/aboutmedicine/ruxolitinib-nella-gestione-della-mielofibrosi 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/aboutmedicine/gestione-medica-di-una-paziente-con-fibromi-uterini-e-desiderio-riproduttivo 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/aboutmedicine/gestione-terapeutica-neoplasia-prostatica-ormono-sensibile-sviluppo-secondarismi-ossei-post-trattamento-primario 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/aboutmedicine/ruxolitinib-nella-gestione-della-mielofibrosi-una-raccolta-di-esperienze-cliniche-vol-2 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/aboutmedicine/ruxolitinib-nella-gestione-della-mielofibrosi-una-raccolta-di-esperienze-cliniche-vol-1 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/aboutmedicine/ottimizzare-la-gestione-terapeutica-della-recidiva-biochimica 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/aboutmedicine/efficacia-della-terapia-medica-combinata-nellipertrofia-prostatica-benigna 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/aboutmedicine/un-modello-per-la-stima-del-costo-unitario-delle-iniezioni-intravitreali 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/aboutmedicine/dutasteride-e-silodosina-trattamento-orale-per-lipertrofia-prostatica-benigna 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/aboutmedicine/trattamento-long-term-con-relugolix-ct-dei-fibromi-uterini 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/aboutmedicine/la-midostaurina-nel-trattamento-della-mastocitosi-sistemica-avanzata-advsm-il-percorso-diagnostico-terapeutico-assistenziale-e-lesperienza-del-policlinico-gemelli-di-roma 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/aboutmedicine/policitemia-vera-e-trombosi-venosa-splancnica-incidenza-diagnosi-e-trattamento 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/aboutmedicine/spondiloartrite-assiale-axspa-i-punti-chiave-per-riconoscerla-e-migliorare-il-percorso-di-gestione-multidisciplinare-dei-pazienti 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/aboutmedicine/le-mutazioni-di-braf-e-met-nel-nsclc-pratica-clinica-e-strategie-a-confronto-2 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/aboutmedicine/fibromatosi-uterina-associata-a-endometriosi-efficacia-e-tollerabilita-di-relugolix-ct-prima-del-trattamento-chirurgico 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/aboutmedicine/trattamento-a-lungo-termine-dei-fibromi-uterini-con-relugolix-40-mg-ct 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/aboutmedicine/malnutrizione-in-oncologia 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/aboutmedicine/gestione-del-paziente-con-carcinoma-della-prostata-ormone-dipendente-esperienze-cliniche 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/aboutmedicine/approccio-multidisciplinare-alla-mucopolisaccaridosi-i-dall-identificazione-precoce-alla-terapia-avanzata 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/aboutmedicine/utilizzo-di-ruxolitinib-nella-gestione-del-paziente-con-policitemia-vera-una-raccolta-di-casi-emblematici-vol-3 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/aboutmedicine/gestione-della-paziente-con-carcinoma-mammario-hr-her2-metastatico-in-trattamento-con-ribociclib-una-collection-di-esperienze-cliniche-a-confronto-vol-2 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/aboutmedicine/one-health-una-salute-unica-una-sola-scienza-protect-our-future-too-from-zoonosis 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/aboutmedicine/personalizzazione-della-scelta-dei-sistemi-cgm-esperienze-di-utilizzo-con-il-dispositivo-dexcom-one 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/aboutmedicine/deferiprone-per-il-trattamento-del-sovraccarico-di-ferro-nella-talassemia 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/aboutmedicine/gestione-della-paziente-con-carcinoma-mammario-hr-her2-metastatico-in-trattamento-con-ribociclib-una-collection-di-esperienze-cliniche-a-confronto-vol-1 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/aboutmedicine/indicatori-di-usabilita-dei-sistemi-di-monitoraggio-in-continuo-del-glucosio-il-punto-di-vista-delle-persone-con-diabete 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/aboutmedicine/le-mutazioni-di-braf-e-met-nel-nsclc-pratica-clinica-e-strategie-a-confronto 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/aboutmedicine/utilizzo-di-ruxolitinib-nella-gestione-del-paziente-con-policitemia-vera-una-raccolta-di-casi-emblematici-vol-2 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/aboutmedicine/gestione-dei-fibromi-uterini-il-potenziale-della-terapia-combinata-con-gli-antagonisti-orali-del-gnrh-2 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/aboutmedicine/melanoma-setting-next-horizon-2023-management-and-targeted-treatment-for-melanoma-braf-patients 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/aboutmedicine/utilizzo-di-ruxolitinib-nella-gestione-del-paziente-con-policitemia-vera-una-raccolta-di-casi-emblematici-vol-1 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/aboutmedicine/rapido-peggioramento-clinico-associato-alla-sospensione-di-everolimus-in-un-giovane-paziente-con-sclerosi-tuberosa 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/aboutmedicine/un-caso-di-sclerosi-tuberosa-dalla-diagnosi-alle-scelte-e-ai-problemi-della-terapia 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/aboutmedicine/efficacia-e-tollerabilita-di-everolimus-in-un-caso-di-epilessia-farmacoresistente-a-esordio-precoce-in-sclerosi-tuberosa 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/aboutmedicine/un-caso-di-epilessia-farmacoresistente-associato-a-tand-tsc 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/aboutmedicine/sindrome-emolitico-uremica 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/aboutmedicine/utilizzo-della-combinazione-dabrafenib-trametinib-nella-gestione-del-paziente-con-nsclc-in-stadio-avanzato-braf-mutato-esperienze-cliniche-vol-2 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/aboutmedicine/approccio-multidisciplinare-per-la-corretta-gestione-del-paziente-con-lombalgia 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/aboutmedicine/orticaria-cronica-spontanea-i-punti-chiave-per-riconoscerla-e-migliorare-il-percorso-di-gestione-dei-pazienti 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/aboutmedicine/melanoma-sliding-doors-2022-management-and-targeted-treatment-for-melanoma-braf-patients 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/aboutmedicine/presa-in-carico-del-paziente-psoriasico-nellinfanzia-nelleta-adulta-e-nelleta-avanzata 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/aboutmedicine/utilizzo-della-combinazione-dabrafenib-trametinib-nella-gestione-del-paziente-con-nsclc 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/aboutmedicine/climax-psicopatologico-uso-di-cariprazina-nel-trattamento-della-doppia-diagnosi 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/aboutmedicine/gestione-clinica-del-paziente-con-mielofiborsi 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/aboutmedicine/gestione-clinica-del-paziente-con-policitemia 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/aboutmedicine/irbesartan-efficacia-oltre-il-controllo-pressorio 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/aboutmedicine/trattamento-dell-endometriosi-esperienze-dalla-pratica-clinica 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/aboutmedicine/la-roche-diabetes-care-platform-un-nuovo-approccio-per-il-monitoraggio-del-paziente-da-remoto-e-la-gestione-personalizzata-del-diabete 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/aboutmedicine/inibitori-delle-chinasi-ciclina-dipendenti-tumore-della-mammella-terapie 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/aboutmedicine/butterfly-effect-lesordio-di-una-psicosi 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/aboutmedicine/pantoprazolo-evidenze-scelta-consolidata 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/aboutmedicine/studio-clinico-combinazione-dabrafenib-trametinib-nsclc-metastatico-braf-mutato 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/aboutmedicine/aboutmedicine-combinazione-dabrafenib-trametinib-algoritmo-terapeutico-nsclc-metastatico-braf-mutato 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/aboutmedicine/colangite-biliare-primitiva-percorsi-diagnostico-terapeutici-emergenza-covid 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/aboutmedicine/trattamento-endometriosi-esperienze-pratica-clinica 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/aboutmedicine/aboutmedicine-setting-adiuvante-melanoma-studio-pubblicazione 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/aboutmedicine/forward-and-beyond-2-0-management-targeted-treatment-melanoma-braf-patients 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/aboutmedicine/optimal-management-systemic-mastocytosis-challenge-hematologists 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/aboutmedicine/studio-secukinumab-in-dermatologia 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/aboutmedicine/trattamento-melanoma-progetto-forward-and-beyond-braf 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/aboutmedicine/effetto-immunomodulante-degli-inibitori-della-tirosina-chinasi-tkis-nel-trattamento-del-carcinoma-renale 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/aboutmedicine/combinazione-paracetamolo-caffeina-cefalea-emicrania-studio 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/aboutmedicine/pubblicazione-speciale-terapia-sistemica-pazienti-adulti-dermatite-atopica 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/aboutmedicine/studio-malattie-infiammatorie-croniche-articolari-multidisciplinare-identificazione-precoce-fattori-rischio-cardiovascolari 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/aboutmedicine/gestione-psicologica-clinica-pazienti-leucemia-mieloide-cronica-aderenza-terapia-treatment-free-remission 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/aboutmedicine/migliorare-assistenza-pazienti-emofilia-studi-clinici-real-world-experience 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/aboutmedicine/melanoma-braf-patient-journey-ideale-trattamento-adiuvante-decision-makers-board 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/aboutmedicine/secukinumab-esperienze-cliniche-confronto-reumatologia-artrite-psoriasica 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/aboutmedicine/sclerosi-multipla-trattamento-precoce-elevata-efficacia-switch-precoce-terapie-elevata-efficacia 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/aboutmedicine/management-paziente-leucemia-mieloide-acuta-trattamento-midostaurina-antifungini-azolici 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/aboutmedicine/ribociclib-linea-trattamento-carcinoma-mammario-avanzato-hr-her2 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/aboutmedicine/value-for-the-future-ripensare-il-presente-per-restituire-il-futuro-roma-30-31-maggio-2019 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/aboutmedicine/terapia-medica-trattamento-fibromi-donne-eta-fertile 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/aboutmedicine/gastrolesivita-fans-paziente-cardiologico 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/aboutmedicine/linfoma-diffuso-a-grandi-cellule-b-dallinnovazione-alla-sostenibilita 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/aboutmedicine/la-diagnosi-clinica-della-dermatite-atopica-delladulto 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/aboutmedicine/rimodulazione-terapia-pazienti-bpco-sospendere-terapia-steroide-inalatorio 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/aboutmedicine/cheratosi-attinica-e-tumori-cutanei-limportanza-di-una-corretta-prevenzione 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/aboutmedicine/frequenti-riacutizzatori-gestione-terapeutica-personalizzata-paziente-bpco 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/aboutmedicine/impatto-sulla-salute-pubblica-della-vaccinazione-con-pcv13-negli-adulti 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/aboutmedicine/secukinumab-esperienze-cliniche-a-confronto-in-dermatologia 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/aboutmedicine/profilassi-e-trattamento-dellemicrania-esperienze-cliniche-con-clevia-e-almogran 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/aboutmedicine/la-gestione-del-paziente-con-malattie-infiammatorie-croniche-intestinali-di-grado-moderato-severo-lo-stato-dellarte-in-italia 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/aboutmedicine/mrge-e-problemi-di-motilita-gastrica-i-consigli-del-gastroenterologo-per-una-gestione-ottimale 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/aboutmedicine/un-racconto-in-evoluzione-biosimilari-e-nuove-opportunita-per-clinici-payer-e-pazienti 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/aboutpharmacoeconomics-eng 2026-04-04T21:17:41.046Z daily 0.7 https://www.helyx.healthcare/aboutpharmacoeconomics-eng/best-practice-nella-psoriasi-pustolosa-generalizzata-gpp3-modelli-organizzativi-per-una-gestione-ottimale-del-patient-journey 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/aboutpharmacoeconomics-eng/efficacia-e-sicurezza-real-world-della-terapia-anticoagulante-orale-con-apixaban-nei-pazienti-con-fibrillazione-atriale-non-valvolare-i-risultati-di-cinque-studi-osservazionali-condotti-in-italia 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/aboutpharmacoeconomics-eng/utilizzo-di-ceftobiprolo-medocaril-sodico-nei-pazienti-ospedalizzati-con-polmonite-evidenze-di-efficacia-sicurezza-e-analisi-di-budget-impact 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/aboutpharmacoeconomics-eng/limpatto-economico-dello-switch-non-clinico-da-enbrel-ai-biosimilari-di-etanercept-nel-trattamento-dellartrite-reumatoide-in-pazienti-stabili-o-in-remissione 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/aboutpharmacoeconomics-eng/la-gestione-del-percorso-assistenziale-nei-day-hospital-oncoematologici-i-risultati-del-progetto-scuba 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/aboutpharmacoeconomics-eng/analisi-di-budget-impact-di-buprenorfina-transdermica-a-basso-dosaggio-nel-trattamento-del-dolore-non-maligno-di-intensita-moderata 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/aboutpharmacoeconomics-eng/confronto-dei-costi-di-gestione-del-monitoraggio-di-pazienti-in-tao-nel-distretto-della-cooperativa-mmg-medici-2000-di-siena 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/aboutpharmacoeconomics-eng/budget-impact-analysis-di-fluticasone-formoterolo-versus-fluticasone-salmeterolo-nel-trattamento-dellasma-in-italia 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/aboutpharmacoeconomics-eng/valutazione-di-costo-efficacia-di-ponatinib-nella-terapia-della-leucemia-mieloide-cronica-in-italia 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/aboutpharmacoeconomics-eng/analisi-di-farmacoutilizzazione-della-terapia-biologica-nel-trattamento-delle-malattie-infiammatorie-immunomediate-i-risultati-di-uno-studio-osservazionale-retrospettivo-condotto-in-italia 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/aboutpharmacoeconomics-eng/aspetti-economico-organizzativi-di-modelli-di-presa-in-carico-di-pazienti-cronici-in-sanita 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/aboutpharmacoeconomics-eng/analisi-di-farmacoutilizzazione-della-terapia-biologica-nel-trattamento-dellartrite-reumatoide-i-risultati-di-uno-studio-osservazionale-retrospettivo-condotto-in-italia 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/aboutpharmacoeconomics-eng/sostenibilita-in-totale-trasparenza 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/aboutpharmacoeconomics 2026-04-04T21:17:41.046Z daily 0.7 https://www.helyx.healthcare/aboutpharmacoeconomics/best-practice-nella-psoriasi-pustolosa-generalizzata-gpp3-modelli-organizzativi-per-una-gestione-ottimale-del-patient-journey 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/aboutpharmacoeconomics/efficacia-e-sicurezza-real-world-della-terapia-anticoagulante-orale-con-apixaban-nei-pazienti-con-fibrillazione-atriale-non-valvolare-i-risultati-di-cinque-studi-osservazionali-condotti-in-italia 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/aboutpharmacoeconomics/utilizzo-di-ceftobiprolo-medocaril-sodico-nei-pazienti-ospedalizzati-con-polmonite-evidenze-di-efficacia-sicurezza-e-analisi-di-budget-impact 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/aboutpharmacoeconomics/limpatto-economico-dello-switch-non-clinico-da-enbrel-ai-biosimilari-di-etanercept-nel-trattamento-dellartrite-reumatoide-in-pazienti-stabili-o-in-remissione 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/aboutpharmacoeconomics/la-gestione-del-percorso-assistenziale-nei-day-hospital-oncoematologici-i-risultati-del-progetto-scuba 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/aboutpharmacoeconomics/analisi-di-budget-impact-di-buprenorfina-transdermica-a-basso-dosaggio-nel-trattamento-del-dolore-non-maligno-di-intensita-moderata 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/aboutpharmacoeconomics/confronto-dei-costi-di-gestione-del-monitoraggio-di-pazienti-in-tao-nel-distretto-della-cooperativa-mmg-medici-2000-di-siena 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/aboutpharmacoeconomics/budget-impact-analysis-fluticasoneformoterolo-versus-fluticasonesalmeterolo-nel-trattamento-dellasma-italia 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/aboutpharmacoeconomics/valutazione-di-costo-efficacia-di-ponatinib-nella-terapia-della-leucemia-mieloide-cronica-in-italia 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/aboutpharmacoeconomics/analisi-di-farmacoutilizzazione-della-terapia-biologica-nel-trattamento-delle-malattie-infiammatorie-immunomediate-i-risultati-di-uno-studio-osservazionale-retrospettivo-condotto-in-italia 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/aboutpharmacoeconomics/aspetti-economico-organizzativi-di-modelli-di-presa-in-carico-di-pazienti-cronici-in-sanita 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/aboutpharmacoeconomics/analisi-di-farmacoutilizzazione-della-terapia-biologica-nel-trattamento-dellartrite-reumatoide-i-risultati-di-uno-studio-osservazionale-retrospettivo-condotto-in-italia 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/aboutpharmacoeconomics/sostenibilita-in-totale-trasparenza 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/aziende 2026-04-04T21:17:41.046Z daily 0.7 https://www.helyx.healthcare/biosimilari-news 2026-04-04T21:17:41.046Z daily 0.7 https://www.helyx.healthcare/books 2026-04-04T21:17:41.046Z daily 0.7 https://www.helyx.healthcare/books/atlante-pratico-di-psoriasi-pediatrica-e-artrite-idiopatica-giovanile 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/books/multimodal-imaging-in-dme-an-update-on-biomarkers-for-clinical-practice 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/books/momenti-dellesserci-nuovi-orizzonti-dellepatite-c 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/books/commercio-parallelo-e-allungamento-del-brevetto-in-ambito-farmaceutico-sviluppo-di-una-sinergia-utile-al-miglioramento-del-welfare 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/books/business-scienza-e-farmaci-lindustria-del-farmaco 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/books/indicazioni-nutrizionali-nutrition-claims-e-sulla-salute-health-claims-e-descrittori-generici-generic-descriptors-in-materia-di-alimenti-e-bevande 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/books/libro-bianco-sul-dolore-cronico 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/books/levoluzione-dellhta-a-livello-aziendale 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/books/healty-ageing-dieci-regole-per-invecchiare-in-buona-salute 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/books/la-salute-dellanziano-e-linvecchiamento-in-buona-salute 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/books/il-libro-bianco-della-sanita 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/books/il-processo-di-budget-e-il-suo-impatto-sul-comportamento-dei-dirigenti-territoriali 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/books/analisi-comparativa-delle-esperienze-di-aggregazione-della-domanda-in-sanita 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/books/lacuisto-dei-farmaci-in-ospedale-2 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/books/industria-farmaceutica-e-sistema-sanitario-un-rapporto-di-valore 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/books/le-sfide-del-sistema-salute-opportunita-innovative-nel-rapporto-pubblico-privato 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/books/farmaci-off-patent-le-interazioni-3 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/books/farmaci-off-patent-le-interazioni-2 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/books/farmaci-off-patent-le-interazioni-1 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/books/il-sistema-dei-prontuari-in-italia 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/books/il-sistema-dei-prontuari-in-italia-2 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/books/siamo-due-lobbisti 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/books/misurare-e-valutare-lintegrazione-professionale-e-la-continuita-delle-cure 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/books/a-look-into-the-future-the-sex-and-gender-pharmacology 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/books/health-value-based-leadership-leadership-creando-valore-per-il-sistema-salute 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/books/lacuisto-dei-farmaci-in-ospedale 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/clinical-brief-eng 2026-04-04T21:17:41.046Z daily 0.7 https://www.helyx.healthcare/clinical-brief-eng/trattamento-della-rosacea-del-volto-in-eta-pediatrica-approccio-terapeutico-con-ivermectina-topica 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/clinical-brief-eng/paziente-con-acne-moderata-e-comorbilita-approccio-terapeutico-con-trifarotene 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/clinical-brief-eng/midostaurina-come-trattamento-di-prima-linea-nella-leucemia-mieloide-acuta-con-mutazione-flt3-positiva-evidenze-dalla-pratica-clinica 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/clinical-brief-eng/midostaurina-come-trattamento-di-prima-linea-nella-mastocitosi-sistemica-avanzata-evidenze-dalla-pratica-clinica 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/clinical-brief-eng/patient-journey-nel-paziente-ad-alto-rischio-cardiovascolare-dec-23 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/clinical-brief-eng/10-anni-regorafenib-italia-milestones-clinici-nel-trattamento-del-mcrc 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/clinical-brief-eng/patient-journey-nel-paziente-a-alto-rischio-cardiovascolare 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/clinical-brief-eng/patient-journey-nel-paziente-ad-alto-rischio-cardiovascolare-4 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/clinical-brief-eng/patient-journey-paziente-alto-rischio-cardiovascolare-4 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/clinical-brief-eng/pazopanib-nel-trattamento-del-sarcoma-dei-tessuti-molli-esperienze-a-confronto 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/clinical-brief-eng/pazopanib-nel-trattamento-di-prima-linea-del-carcinoma-renale-avanzato-esperienze-a-confronto 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/clinical-brief-eng/patient-journey-nel-paziente-ad-alto-rischio-cardiovascolare-3 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/clinical-brief-eng/patient-journey-nel-paziente-ad-alto-rischio-cardiovascolare 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/clinical-brief-eng/patient-journey-nel-paziente-ad-alto-rischio-cardiovascolare-2 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/clinical-brief-eng/ruxolitinib-nel-trattamento-delle-neoplasie-mieloproliferative-esperienze-a-confronto-in-liguria 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/clinical-brief-eng/ruxolitinib-nel-trattamento-delle-neoplasie-mieloproliferative-esperienze-a-confronto-in-liguria-2 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/clinical-brief-eng/early-mf-what-does-it-mean 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/clinical-brief-eng/early-mf-what-does-it-mean-2 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/clinical-brief-eng/limportanza-dellapproccio-multidisciplinare-in-policitemia-vera-dalla-diagnosi-al-follow-up 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/clinical-brief-eng/gestione-ottimale-dei-pazienti-con-sarcomi-dei-tessuti-molli-sts-evidenze-dalla-clinical-practice-un-focus-sui-sarcomi-sinoviali 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/clinical-brief-eng/gestione-ottimale-dei-pazienti-con-sarcomi-dei-tessuti-molli-sts-evidenze-dalla-clinical-practice-un-focus-sui-leiomiosarcomi-uterini 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/clinical-brief-eng/il-valore-della-vaccinazione-pneumococcica-e-meningococcica-in-pediatria 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/clinical-brief-eng/carcinoma-mammario-metastatico-hr-her2-everolimus-nelle-pazienti-con-malattia-indolente-dopo-progressione-ad-una-prima-linea-ormonale 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/clinical-brief-eng/everolimus-piu-exemestane-come-terapia-metastatica-di-prima-linea-in-pazienti-con-carcinoma-mammario-hr-her2-in-ricaduta-precoce-dopo-il-termine-del-trattamento-adiuvante-con-inibitori-dell 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/clinical-brief-eng/carcinoma-mammario-metastatico-hr-her2-trattamento-di-prima-linea-con-everolimus-in-pazienti-in-ricaduta-durante-terapia-adiuvante 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/clinical-brief 2026-04-04T21:17:41.046Z daily 0.7 https://www.helyx.healthcare/clinical-brief/paziente-con-acne-moderata-e-comorbilita-approccio-terapeutico-con-trifarotene 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/clinical-brief/trattamento-della-rosacea-del-volto-in-eta-pediatrica-approccio-terapeutico-con-ivermectina-topica 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/clinical-brief/midostaurina-come-trattamento-di-prima-linea-nella-leucemia-mieloide-acuta-con-mutazione-flt3-positiva-evidenze-dalla-pratica-clinica 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/clinical-brief/midostaurina-come-trattamento-di-prima-linea-nella-mastocitosi-sistemica-avanzata-evidenze-dalla-pratica-clinica 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/clinical-brief/patient-journey-nel-paziente-ad-alto-rischio-cardiovascolare-dic-23 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/clinical-brief/10-anni-regorafenib-italia-milestones-clinici-nel-trattamento-del-mcrc 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/clinical-brief/patient-journey-nel-paziente-a-alto-rischio-cardiovascolare 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/clinical-brief/patient-journey-paziente-ad-alto-rischio-cardiovascolare 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/clinical-brief/patient-journey-paziente-alto-rischio-cardiovascolare-4 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/clinical-brief/pazopanib-nel-trattamento-del-sarcoma-dei-tessuti-molli-esperienze-a-confronto 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/clinical-brief/pazopanib-nel-trattamento-di-prima-linea-del-carcinoma-renale-avanzato-esperienze-a-confronto 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/clinical-brief/patient-journey-nel-paziente-ad-alto-rischio-cardiovascolare-3 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/clinical-brief/brief-patient-journey-paziente-alto-rischio-cardiovascolare 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/clinical-brief/patient-journey-nel-paziente-ad-alto-rischio-cardiovascolare 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/clinical-brief/ruxolitinib-trattamento-neoplasie-mieloproliferative-liguria-pv 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/clinical-brief/ruxolitinib-trattamento-neoplasie-mieloproliferative-liguria 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/clinical-brief/mielofibrosi-primaria-ruxolitinib-pazienti-int-1-ipss 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/clinical-brief/early-mf-stato-arte-partica-clinica-mielofibrosi-primaria 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/clinical-brief/importanza-approccio-multidisciplinare-policitemia-vera-diagnosi-followup 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/clinical-brief/gestione-ottimale-dei-pazienti-con-sarcomi-dei-tessuti-molli-sts-evidenze-dalla-clinical-practice-un-focus-sui-sarcomi-sinoviali 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/clinical-brief/gestione-ottimale-dei-pazienti-con-sarcomi-dei-tessuti-molli-sts-evidenze-dalla-clinical-practice-un-focus-sui-leiomiosarcomi-uterini 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/clinical-brief/valore-della-vaccinazione-pneumococcica-meningococcica-pediatria 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/clinical-brief/carcinoma-mammario-metastatico-hrher2-everolimus-nelle-pazienti-malattia-indolente-progressione-ad-linea-ormonale 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/clinical-brief/everolimus-piu-exemestane-terapia-metastatica-linea-pazienti-carcinoma-mammario-hrher2-ricaduta-precoce-termine-del-trattamento-adiuvante-inibitori-dell 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/clinical-brief/carcinoma-mammario-metastatico-hrher2-trattamento-linea-everolimus-pazienti-ricaduta-terapia-adiuvante 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/clinical-outcomes-eng 2026-04-04T21:17:41.046Z daily 0.7 https://www.helyx.healthcare/clinical-outcomes-eng/everolimus-nella-gestione-dellepilessia-refrattaria-associata-a-sclerosi-tuberosa 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/clinical-outcomes-eng/la-terapia-multimodale-del-dolore-in-funzione-della-tipologia-di-paziente 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/clinical-outcomes-eng/la-vaccinazione-contro-il-meningococco-b 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/clinical-outcomes-eng/trabectedina-in-combinazione-con-doxorubicina-liposomiale-pegilata-nel-trattamento-della-recidiva-di-carcinoma-ovarico-nelle-pazienti-parzialmente-platino-sensibili 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/clinical-outcomes-eng/approccio-diagnostico-terapeutico-pratico-alla-sindrome-dellintestino-irritabile 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/clinical-outcomes-eng/confronto-diretto-dellimmunogenicita-indotta-dai-vaccini-coniugati-10-valente-e-13-valente-nel-periodo-della-dose-booster-a-11-mesi-di-eta-in-bambini-olandesi 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/clinical-outcomes-eng/la-terapia-con-abatacept-nellartrite-reumatoide-precoce-e-rapidamente-progressiva-alla-luce-del-ruolo-degli-acpa 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/clinical-outcomes-eng/limportanza-del-microbiota-intestinale-per-il-benessere-psicofisico-della-donna 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/clinical-outcomes-eng/ruolo-chiave-del-vaccino-pneumococcico-polisaccaridico-coniugato-13-valente-pcv13-nella-prevenzione-delle-infezioni-da-s-pneumoniae 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/clinical-outcomes-eng/infezioni-respiratorie-ricorrenti-e-biofilm-batterici-ruolo-di-tiamfenicolo-glicinato-acetilcisteinato 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/clinical-outcomes-eng/la-modulazione-della-costimolazione-dei-linfociti-t-come-terapia-di-prima-linea-biologica-in-artrite-reumatoide-evidenze-da-trial-head-to-head 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/clinical-outcomes 2026-04-04T21:17:41.046Z daily 0.7 https://www.helyx.healthcare/clinical-outcomes/everolimus-epilessia-refrattaria-sclerosi-tuberosa 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/clinical-outcomes/terapia-multimodale-dolore-tipologia-paziente 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/clinical-outcomes/la-vaccinazione-contro-il-meningococco-b 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/clinical-outcomes/trabectedina-combinazione-doxorubicina-liposomiale-pegilata-nel-trattamento-della-recidiva-carcinoma-ovarico-nelle-pazienti-parzialmente-platino-sensibili 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/clinical-outcomes/approccio-diagnosticoterapeutico-pratico-alla-sindrome-dellintestino-irritabile 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/clinical-outcomes/confronto-diretto-dellimmunogenicita-indotta-dai-vaccini-coniugati-10-valente-13-valente-nel-periodo-della-dose-booster-11-mesi-eta-bambini-olandesi 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/clinical-outcomes/la-terapia-con-abatacept-nellartrite-reumatoide-precoce-e-rapidamente-progressiva-alla-luce-del-ruolo-degli-acpa 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/clinical-outcomes/l-importanza-del-microbiota-intestinale-per-il-benessere-psicofisico-della-donna 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/clinical-outcomes/ruolo-chiave-del-vaccino-pneumococcico-polisaccaridico-coniugato-13-valente-pcv13-nella-prevenzione-delle-infezioni-da-s-pneumoniae 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/clinical-outcomes/infezioni-respiratorie-ricorrenti-e-biofilm-batterici-ruolo-di-tiamfenicolo-glicinato-acetilcisteinato-3 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/clinical-outcomes/clinical-outcomes-la-modulazione-la-modulazione-della-costimolazione-dei-linfociti-t-come-terapia-di-prima-linea-biologica-in-artrite-reumatoide-evidenze-da-trial-head-to-head-2 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/convegni-abouteducation 2026-04-04T21:17:41.046Z daily 0.7 https://www.helyx.healthcare/fightingpain-news 2026-04-04T21:17:41.046Z daily 0.7 https://www.helyx.healthcare/formazione-abouteducation 2026-04-04T21:17:41.046Z daily 0.7 https://www.helyx.healthcare/home-page 2026-04-04T21:17:41.046Z daily 0.7 https://www.helyx.healthcare/home-page/la-gestione-del-percorso-assistenziale-nei-day-hospital-oncoematologici-i-risultati-del-progetto-scuba 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/home-page/infezioni-respiratorie-ricorrenti-e-biofilm-batterici-ruolo-di-tiamfenicolo-glicinato-acetilcisteinato-3 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/home-page/resveratrolo-una-nuova-tecnologia-per-potenziarne-l-efficacia-3 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/hta-news 2026-04-04T21:17:41.046Z daily 0.7 https://www.helyx.healthcare/whitepaper-aboutpharma 2026-04-04T21:17:41.046Z daily 0.7 https://www.helyx.healthcare/innovations-in-eng 2026-04-04T21:17:41.046Z daily 0.7 https://www.helyx.healthcare/innovations-in-eng/gestione-del-carcinoma-ovarico-di-alto-grado-evidenze-della-pratica-clinica-e-importanza-della-caratterizzazione-molecolare 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/innovations-in-eng/fulvestrant-nel-trattamento-del-carcinoma-mammario-metastatico-hr-her2-evidenze-dalla-pratica-clinica 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/innovations-in-eng/ipertensione-e-insonnia 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/innovations-in-eng/probiotici-quali-quanti-e-quando 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/innovations-in-eng/ergonomia-e-raccomandazioni-per-la-gestione-della-mano-osteoartrosica 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/innovations-in-eng/linee-guida-idsa-2013-in-pratica-clinica-per-la-vaccinazione-dei-pazienti-immunocompromessi 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/innovations-in-eng/outcome-economico-sanitari-a-breve-termine-della-terapia-insulinica-sottocutanea-continua-con-microinfusore-csii-nel-diabete-di-tipo-1-analisi-comparativa-dei-costi 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/innovations-in 2026-04-04T21:17:41.046Z daily 0.7 https://www.helyx.healthcare/innovations-in/gestione-del-carcinoma-ovarico-di-alto-grado-evidenze-della-pratica-clinica-e-importanza-della-caratterizzazione-molecolare 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/innovations-in/fulvestrant-nel-trattamento-del-carcinoma-mammario-metastatico-hr-her2-evidenze-dalla-pratica-clinica 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/innovations-in/ipertensione-e-insonnia 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/innovations-in/probiotici-quali-quanti 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/innovations-in/ergonomia-raccomandazioni-la-gestione-della-mano-osteoartrosica 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/innovations-in/linee-guida-idsa-2013-pratica-clinica-per-la-vaccinazione-dei-pazienti-immunocompromessi 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/innovations-in/outcome-economico-sanitari-a-breve-termine-della-terapia-insulinica-sottocutanea-continua-con-microinfusore-csii-nel-diabete-di-tipo-1-analisi-comparativa-dei-costi 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/libri 2026-04-04T21:17:41.046Z daily 0.7 https://www.helyx.healthcare/libri/atlante-pratico-di-psoriasi-pediatrica-e-artrite-idiopatica-giovanile 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/libri/multimodal-imaging-in-dme-an-update-on-biomarkers-for-clinical-practice 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/libri/momenti-dellesserci-nuovi-orizzonti-dellepatite-c 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/libri/commercio-parallelo-e-allungamento-del-brevetto-in-ambito-farmaceutico-sviluppo-di-una-sinergia-utile-al-miglioramento-del-welfare 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/libri/business-scienza-e-farmaci-lindustria-del-farmaco 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/libri/indicazioni-nutrizionali-nutrition-claims-e-sulla-salute-health-claims-e-descrittori-generici-generic-descriptors-in-materia-di-alimenti-e-bevande 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/libri/libro-bianco-sul-dolore-cronico 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/libri/levoluzione-dellhta-a-livello-aziendale 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/libri/healty-ageing-dieci-regole-per-invecchiare-in-buona-salute 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/libri/la-salute-dellanziano-e-linvecchiamento-in-buona-salute 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/libri/il-libro-bianco-della-sanita 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/libri/il-processo-di-budget-e-il-suo-impatto-sul-comportamento-dei-dirigenti-territoriali 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/libri/analisi-comparativa-delle-esperienze-di-aggregazione-della-domanda-in-sanita 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/libri/lacuisto-dei-farmaci-in-ospedale-2 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/libri/industria-farmaceutica-e-sistema-sanitario-un-rapporto-di-valore 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/libri/le-sfide-del-sistema-salute-opportunita-innovative-nel-rapporto-pubblico-privato 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/libri/farmaci-off-patent-le-interazioni-3 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/libri/farmaci-off-patent-le-interazioni-2 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/libri/farmaci-off-patent-le-interazioni-1 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/libri/il-sistema-dei-prontuari-in-italia 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/libri/il-sistema-dei-prontuari-in-italia-2 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/libri/siamo-due-lobbisti 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/libri/misurare-e-valutare-lintegrazione-professionale-e-la-continuita-delle-cure 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/libri/a-look-into-the-future-the-sex-and-gender-pharmacology 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/libri/health-value-based-leadership-leadership-creando-valore-per-il-sistema-salute 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/libri/lacuisto-dei-farmaci-in-ospedale 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/scienza-ricerca 2026-04-04T21:17:41.046Z daily 0.7 https://www.helyx.healthcare/news-filter 2026-04-04T21:17:41.046Z daily 0.7 https://www.helyx.healthcare/non-categorizzato 2026-04-04T21:17:41.046Z daily 0.7 https://www.helyx.healthcare/non-categorizzato/spot-opt-oculistica 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/non-categorizzato/fulvestrant-nel-trattamento-del-carcinoma-mammario-metastatico-hr-her2-evidenze-dalla-pratica-clinica-2 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/non-categorizzato/sclerosi-multipla-trattamento-precoce-elevata-efficacia-switch-precoce-terapie-elevata-efficacia 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/non-categorizzato/rimodulazione-terapia-pazienti-bpco-sospendere-terapia-steroide-inalatorio 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/non-categorizzato/trattamento-del-carcinoma-mammario-metastatico-hrher2-nella-paziente-post-menopausa-dalla-letteratura-alla-pratica-clinica 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/non-categorizzato/trattamento-del-carcinoma-mammario-metastatico-hrher2-nella-paziente-post-menopausa-dalla-letteratura-alla-pratica-clinica-criteri-selezione-della-paziente-sequenza-terapeutica-ot 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/non-categorizzato/interazioni-farmacologiche-di-alogliptin-e-impiego-nellanziano 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/non-categorizzato/gestione-del-paziente-trattato-a-lungo-termine-con-lamivudina-fattori-correlati-con-linsorgenza-di-resistenza-e-implicazioni-per-il-pro-active-switch 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/optin-en 2026-04-04T21:17:41.046Z daily 0.7 https://www.helyx.healthcare/optin-en/linee-guida-esh-2023-la-scelta-della-terapia-antiipertensiva 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/persone-e-professioni 2026-04-04T21:17:41.046Z daily 0.7 https://www.helyx.healthcare/politica 2026-04-04T21:17:41.046Z daily 0.7 https://www.helyx.healthcare/pubblicazioni 2026-04-04T21:17:41.046Z daily 0.7 https://www.helyx.healthcare/pubblicazioni/spot-opt-oculistica 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/pubblicazioni/colchicina-nella-modulazione-ad-ampio-spettro-dellinfiammazione-evidenze-cliniche-in-cardiologia-e-in-reumatologia 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/pubblicazioni/relugolix-ct-nella-gestione-di-pazienti-affette-da-endometriosi-esperienze-dalla-pratica-clinica 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/pubblicazioni/il-sistema-aid-tandem-mobi-documento-di-consenso-di-un-panel-di-esperti-italiani-per-la-selezione-del-paziente-e-lutilizzo-clinico 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/pubblicazioni/terapia-di-combinazione-nel-paziente-affetto-da-ipertrofia-prostatica-benigna-quanto-e-ancora-attuale 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/pubblicazioni/leuprorelina-acetato-come-trattamento-di-base-per-il-carcinoma-prostatico-metastatico-brca-mutato 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/pubblicazioni/approcci-innovativi-di-empirica-ragionata-nella-gestione-delle-infezioni-ospedaliere-da-gram-negativi-multi-resistenti-agli-antibiotici 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/pubblicazioni/carcinoma-prostatico-localmente-avanzato-in-un-uomo-di-56-anni-gestione-con-terapia-antiandrogenica-prima-della-stadiazione 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/pubblicazioni/paziente-con-acne-moderata-e-comorbilita-approccio-terapeutico-con-trifarotene 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/pubblicazioni/trattamento-della-rosacea-del-volto-in-eta-pediatrica-approccio-terapeutico-con-ivermectina-topica 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/pubblicazioni/trattamento-combinato-con-silodosina-e-dutasteride-in-paziente-con-ipertrofia-prostatica-benigna 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/pubblicazioni/ruxolitinib-nella-gestione-della-mielofibrosi 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/pubblicazioni/gestione-medica-di-una-paziente-con-fibromi-uterini-e-desiderio-riproduttivo 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/pubblicazioni/gestione-terapeutica-neoplasia-prostatica-ormono-sensibile-sviluppo-secondarismi-ossei-post-trattamento-primario 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/pubblicazioni/ruxolitinib-nella-gestione-della-mielofibrosi-una-raccolta-di-esperienze-cliniche-vol-2 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/pubblicazioni/ruxolitinib-nella-gestione-della-mielofibrosi-una-raccolta-di-esperienze-cliniche-vol-1 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/pubblicazioni/ottimizzare-la-gestione-terapeutica-della-recidiva-biochimica 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/pubblicazioni/efficacia-della-terapia-medica-combinata-nellipertrofia-prostatica-benigna 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/pubblicazioni/un-modello-per-la-stima-del-costo-unitario-delle-iniezioni-intravitreali 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/pubblicazioni/dutasteride-e-silodosina-trattamento-orale-per-lipertrofia-prostatica-benigna 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/pubblicazioni/trattamento-long-term-con-relugolix-ct-dei-fibromi-uterini 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/pubblicazioni/midostaurina-come-trattamento-di-prima-linea-nella-leucemia-mieloide-acuta-con-mutazione-flt3-positiva-evidenze-dalla-pratica-clinica 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/pubblicazioni/la-midostaurina-nel-trattamento-della-mastocitosi-sistemica-avanzata-advsm-il-percorso-diagnostico-terapeutico-assistenziale-e-lesperienza-del-policlinico-gemelli-di-roma 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/pubblicazioni/policitemia-vera-e-trombosi-venosa-splancnica-incidenza-diagnosi-e-trattamento 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/pubblicazioni/spondiloartrite-assiale-axspa-i-punti-chiave-per-riconoscerla-e-migliorare-il-percorso-di-gestione-multidisciplinare-dei-pazienti 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/pubblicazioni/midostaurina-come-trattamento-di-prima-linea-nella-mastocitosi-sistemica-avanzata-evidenze-dalla-pratica-clinica 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/pubblicazioni/le-mutazioni-di-braf-e-met-nel-nsclc-pratica-clinica-e-strategie-a-confronto-2 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/pubblicazioni/fibromatosi-uterina-associata-a-endometriosi-efficacia-e-tollerabilita-di-relugolix-ct-prima-del-trattamento-chirurgico 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/pubblicazioni/trattamento-a-lungo-termine-dei-fibromi-uterini-con-relugolix-40-mg-ct 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/pubblicazioni/malnutrizione-in-oncologia 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/pubblicazioni/gestione-del-paziente-con-carcinoma-della-prostata-ormone-dipendente-esperienze-cliniche 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/pubblicazioni/linee-guida-esh-2023-la-scelta-della-terapia-antiipertensiva 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/pubblicazioni/approccio-multidisciplinare-alla-mucopolisaccaridosi-i-dall-identificazione-precoce-alla-terapia-avanzata 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/pubblicazioni/utilizzo-di-ruxolitinib-nella-gestione-del-paziente-con-policitemia-vera-una-raccolta-di-casi-emblematici-vol-3 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/pubblicazioni/gestione-della-paziente-con-carcinoma-mammario-hr-her2-metastatico-in-trattamento-con-ribociclib-una-collection-di-esperienze-cliniche-a-confronto-vol-2 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/pubblicazioni/one-health-una-salute-unica-una-sola-scienza-protect-our-future-too-from-zoonosis 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/pubblicazioni/personalizzazione-della-scelta-dei-sistemi-cgm-esperienze-di-utilizzo-con-il-dispositivo-dexcom-one 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/pubblicazioni/deferiprone-per-il-trattamento-del-sovraccarico-di-ferro-nella-talassemia 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/pubblicazioni/gestione-della-paziente-con-carcinoma-mammario-hr-her2-metastatico-in-trattamento-con-ribociclib-una-collection-di-esperienze-cliniche-a-confronto-vol-1 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/pubblicazioni/patient-journey-nel-paziente-ad-alto-rischio-cardiovascolare-dic-23 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/pubblicazioni/indicatori-di-usabilita-dei-sistemi-di-monitoraggio-in-continuo-del-glucosio-il-punto-di-vista-delle-persone-con-diabete 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/pubblicazioni/le-mutazioni-di-braf-e-met-nel-nsclc-pratica-clinica-e-strategie-a-confronto 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/pubblicazioni/utilizzo-di-ruxolitinib-nella-gestione-del-paziente-con-policitemia-vera-una-raccolta-di-casi-emblematici-vol-2 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/pubblicazioni/gestione-dei-fibromi-uterini-il-potenziale-della-terapia-combinata-con-gli-antagonisti-orali-del-gnrh-2 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/pubblicazioni/melanoma-setting-next-horizon-2023-management-and-targeted-treatment-for-melanoma-braf-patients 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/pubblicazioni/utilizzo-di-ruxolitinib-nella-gestione-del-paziente-con-policitemia-vera-una-raccolta-di-casi-emblematici-vol-1 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/pubblicazioni/rapido-peggioramento-clinico-associato-alla-sospensione-di-everolimus-in-un-giovane-paziente-con-sclerosi-tuberosa 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/pubblicazioni/un-caso-di-sclerosi-tuberosa-dalla-diagnosi-alle-scelte-e-ai-problemi-della-terapia 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/pubblicazioni/efficacia-e-tollerabilita-di-everolimus-in-un-caso-di-epilessia-farmacoresistente-a-esordio-precoce-in-sclerosi-tuberosa 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/pubblicazioni/un-caso-di-epilessia-farmacoresistente-associato-a-tand-tsc 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/pubblicazioni/sindrome-emolitico-uremica 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/pubblicazioni/10-anni-regorafenib-italia-milestones-clinici-nel-trattamento-del-mcrc 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/pubblicazioni/patient-journey-nel-paziente-a-alto-rischio-cardiovascolare 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/pubblicazioni/utilizzo-della-combinazione-dabrafenib-trametinib-nella-gestione-del-paziente-con-nsclc-in-stadio-avanzato-braf-mutato-esperienze-cliniche-vol-2 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/pubblicazioni/approccio-multidisciplinare-per-la-corretta-gestione-del-paziente-con-lombalgia 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/pubblicazioni/best-practice-nella-psoriasi-pustolosa-generalizzata-gpp3-modelli-organizzativi-per-una-gestione-ottimale-del-patient-journey 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/pubblicazioni/orticaria-cronica-spontanea-i-punti-chiave-per-riconoscerla-e-migliorare-il-percorso-di-gestione-dei-pazienti 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/pubblicazioni/melanoma-sliding-doors-2022-management-and-targeted-treatment-for-melanoma-braf-patients 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/pubblicazioni/patient-journey-paziente-ad-alto-rischio-cardiovascolare 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/pubblicazioni/presa-in-carico-del-paziente-psoriasico-nellinfanzia-nelleta-adulta-e-nelleta-avanzata 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/pubblicazioni/utilizzo-della-combinazione-dabrafenib-trametinib-nella-gestione-del-paziente-con-nsclc 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/pubblicazioni/patient-journey-paziente-alto-rischio-cardiovascolare-4 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/pubblicazioni/pazopanib-nel-trattamento-del-sarcoma-dei-tessuti-molli-esperienze-a-confronto 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/pubblicazioni/pazopanib-nel-trattamento-di-prima-linea-del-carcinoma-renale-avanzato-esperienze-a-confronto 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/pubblicazioni/climax-psicopatologico-uso-di-cariprazina-nel-trattamento-della-doppia-diagnosi 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/pubblicazioni/gestione-clinica-del-paziente-con-mielofiborsi 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/pubblicazioni/gestione-clinica-del-paziente-con-policitemia 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/pubblicazioni/irbesartan-efficacia-oltre-il-controllo-pressorio 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/pubblicazioni/trattamento-dell-endometriosi-esperienze-dalla-pratica-clinica 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/pubblicazioni/la-roche-diabetes-care-platform-un-nuovo-approccio-per-il-monitoraggio-del-paziente-da-remoto-e-la-gestione-personalizzata-del-diabete 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/pubblicazioni/patient-journey-nel-paziente-ad-alto-rischio-cardiovascolare-3 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/pubblicazioni/everolimus-epilessia-refrattaria-sclerosi-tuberosa 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/pubblicazioni/brief-patient-journey-paziente-alto-rischio-cardiovascolare 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/pubblicazioni/studio-clinico-combinazione-dabrafenib-trametinib-nsclc-metastatico-braf-mutato 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/pubblicazioni/patient-journey-nel-paziente-ad-alto-rischio-cardiovascolare 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/pubblicazioni/aboutmedicine-combinazione-dabrafenib-trametinib-algoritmo-terapeutico-nsclc-metastatico-braf-mutato 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/pubblicazioni/colangite-biliare-primitiva-percorsi-diagnostico-terapeutici-emergenza-covid 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/pubblicazioni/trattamento-endometriosi-esperienze-pratica-clinica 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/pubblicazioni/ruxolitinib-trattamento-neoplasie-mieloproliferative-liguria-pv 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/pubblicazioni/ruxolitinib-trattamento-neoplasie-mieloproliferative-liguria 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/pubblicazioni/aboutmedicine-setting-adiuvante-melanoma-studio-pubblicazione 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/pubblicazioni/terapia-multimodale-dolore-tipologia-paziente 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/pubblicazioni/forward-and-beyond-2-0-management-targeted-treatment-melanoma-braf-patients 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/pubblicazioni/optimal-management-systemic-mastocytosis-challenge-hematologists 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/pubblicazioni/studio-secukinumab-in-dermatologia 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/pubblicazioni/trattamento-melanoma-progetto-forward-and-beyond-braf 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/pubblicazioni/mielofibrosi-primaria-ruxolitinib-pazienti-int-1-ipss 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/pubblicazioni/effetto-immunomodulante-degli-inibitori-della-tirosina-chinasi-tkis-nel-trattamento-del-carcinoma-renale 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/pubblicazioni/combinazione-paracetamolo-caffeina-cefalea-emicrania-studio 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/pubblicazioni/pubblicazione-speciale-terapia-sistemica-pazienti-adulti-dermatite-atopica 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/pubblicazioni/studio-malattie-infiammatorie-croniche-articolari-multidisciplinare-identificazione-precoce-fattori-rischio-cardiovascolari 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/pubblicazioni/gestione-psicologica-clinica-pazienti-leucemia-mieloide-cronica-aderenza-terapia-treatment-free-remission 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/pubblicazioni/migliorare-assistenza-pazienti-emofilia-studi-clinici-real-world-experience 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/pubblicazioni/melanoma-braf-patient-journey-ideale-trattamento-adiuvante-decision-makers-board 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/pubblicazioni/early-mf-stato-arte-partica-clinica-mielofibrosi-primaria 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/pubblicazioni/secukinumab-esperienze-cliniche-confronto-reumatologia-artrite-psoriasica 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/pubblicazioni/sclerosi-multipla-trattamento-precoce-elevata-efficacia-switch-precoce-terapie-elevata-efficacia 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/pubblicazioni/importanza-approccio-multidisciplinare-policitemia-vera-diagnosi-followup 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/pubblicazioni/management-paziente-leucemia-mieloide-acuta-trattamento-midostaurina-antifungini-azolici 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/pubblicazioni/ribociclib-linea-trattamento-carcinoma-mammario-avanzato-hr-her2 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/regioni 2026-04-04T21:17:41.046Z daily 0.7 https://www.helyx.healthcare/riviste-pubblicazioni 2026-04-04T21:17:41.046Z daily 0.7 https://www.helyx.healthcare/riviste-pubblicazioni/everolimus-epilessia-refrattaria-sclerosi-tuberosa 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/riviste-pubblicazioni/ruxolitinib-trattamento-neoplasie-mieloproliferative-liguria-pv 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/riviste-pubblicazioni/ruxolitinib-trattamento-neoplasie-mieloproliferative-liguria 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/riviste-pubblicazioni/terapia-multimodale-dolore-tipologia-paziente 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/riviste-pubblicazioni/early-mf-stato-arte-partica-clinica-mielofibrosi-primaria 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/riviste-pubblicazioni/importanza-approccio-multidisciplinare-policitemia-vera-diagnosi-followup 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/sanita-e-politica 2026-04-04T21:17:41.046Z daily 0.7 https://www.helyx.healthcare/optin 2026-04-04T21:17:41.046Z daily 0.7 https://www.helyx.healthcare/optin/linee-guida-esh-2023-la-scelta-della-terapia-antiipertensiva 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/speciali 2026-04-04T21:17:41.046Z daily 0.7 https://www.helyx.healthcare/uncategorized 2026-04-04T21:17:41.046Z daily 0.7 https://www.helyx.healthcare/uncategorized/sclerosi-multipla-trattamento-precoce-a-elevata-efficacia-e-switch-precoce-a-terapie-a-elevata-efficacia 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/uncategorized/rimodulazione-dellappropriatezza-terapeutica-nei-pazienti-con-bpco-quando-come-e-in-quali-pazienti-sospendere-la-terapia-con-steroide-inalatorio 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/uncategorized/trattamento-del-carcinoma-mammario-metastatico-hr-her2-nella-paziente-in-post-menopausa-dalla-letteratura-alla-pratica-clinica 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/uncategorized/trattamento-del-carcinoma-mammario-metastatico-hr-her2-nella-paziente-in-post-menopausa-dalla-letteratura-alla-pratica-clinica-criteri-di-selezione-della-paziente-e-sequenza-terapeutica-ot 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/uncategorized/interazioni-farmacologiche-di-alogliptin-e-impiego-nellanziano 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/uncategorized/gestione-del-paziente-trattato-a-lungo-termine-con-lamivudina-fattori-correlati-con-linsorgenza-di-resistenza-e-implicazioni-per-il-pro-active-switch 2026-04-04T21:17:41.046Z daily 0.6 https://www.helyx.healthcare/video 2026-04-04T21:17:41.046Z daily 0.7 https://www.helyx.healthcare/web-tech 2026-04-04T21:17:41.046Z daily 0.7